Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25305481 | 0.83 | MEN1 (0.36) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL29483851 | 0.83 | MEN1 (0.36) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL26969840 | 0.79 | KLKB1 (0.41) | MAPTALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL30708788 | 0.79 | KLKB1 (0.41) | MAPTALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL30708864 | 0.79 | MEN1 (0.40) | MAPTALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL26969996 | 0.79 | MEN1 (0.40) | MAPTALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL29483850 | 0.78 | NR1H2 (0.39) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL25263840 | 0.78 | NR1H2 (0.39) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL30708743 | 0.74 | MAPT (0.39) | MAPTALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL30708789 | 0.74 | MAPT (0.41) | MAPTALDH1A1PKML3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210694-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4210694-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022056051-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | MAPT 781/4885ALDH1A1 1701/4885PKM 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.